|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1ST TIME HERE?.....CLICK THE FLASHING RED BUTTON ON THE LEFT! | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
August 07, 2005Oral Drug That May Boost Walking Function in MS to be Tested
Click to read complete articleThe medication, labeled Fampridine-SR, is the sustained-release, oral form of the investigational drug, Fampridine. According to its manufacturer, Acorda Therapeutics, the drug is currently being tested in several clinical trials as a therapy for both MS and spinal cord injury. In preclinical trials, the drug has been shown to improve impulse conduction in nerve fibers after myelin has been damaged.
|